Drug Delivery (Part V): Microneedle Technology—The Painless Revolution in Transdermal Delivery
Apr 13, 2026
Drug Delivery (Part V): Microneedle Technology-The "Painless" Revolution in Transdermal Delivery
Among the "Top Ten Emerging Technologies of 2020" selected by Scientific American, painless microneedle injection technology ranked first. With its potential to surpass traditional delivery methods, this technology has garnered significant attention from both the scientific community and industry.
I. Technical Overview: Breaching the Skin Barrier
Microneedles (MNs) are array-based physical permeation enhancers typically ranging from 10 to 2,000 µm in length. They penetrate the stratum corneum-the primary barrier to transdermal absorption-to create micron-scale channels in the epidermis or upper dermis, allowing drugs to bypass the stratum corneum and enter the microcirculation directly. Unlike conventional transdermal patches, which are limited to small, lipophilic molecules (MW < 500 Da), microneedle technology vastly expands the scope of deliverable therapeutics to include macromolecular biologics such as peptides, proteins, and nucleic acids.
II. Evolutionary History: From Concept to Industrialization
The concept of microneedles was first proposed by Alan Richard Wagner in 1958, but remained stagnant due to limitations in fabrication technology. In 1995, with the advent of Micro-Electro-Mechanical Systems (MEMS), Hashmi et al. successfully fabricated the first microneedle arrays on silicon wafers. In 1998, Henry's team at Georgia Tech applied the technology to transdermal drug delivery, marking the formal entry of microneedles into the pharmaceutical domain.
III. Mainstream Classification and Technological Iteration
Microneedle technology has undergone four generations of iteration. Based on functionality, they are categorized as follows:
Solid Microneedles (Poke and Patch): The earliest type, which creates microchannels via "puncture first, apply drug later." However, these channels close rapidly due to skin healing, and there is a risk of needle breakage.
Hollow Microneedles: Functioning like miniature syringes, these offer high loading capacity and precise dosing but involve complex manufacturing processes and high costs, with a risk of needle blockage.
Coated Microneedles (Coat and Poke): Drugs are coated onto the needle surface and released rapidly upon insertion. While versatile, their payload is limited by the surface area.
Dissolving Microneedles (Poke and Release): The current industry mainstream. Fabricated from biodegradable materials like Hyaluronic Acid (HA) or polymers, the needle body dissolves completely upon insertion, releasing the drug without generating sharps waste. This method is painless, safe, and cost-effective for mass production.
Hydrogel-Forming Microneedles: These swell upon insertion to form a gel network, creating sustained diffusion channels that combine the advantages of hollow and dissolving systems.
Cryo Microneedles: An emerging technology for the transdermal delivery of living cells (e.g., Dendritic Cell vaccines) under cryogenic conditions, offering a novel strategy for cell therapy.
IV. Industrial Status and Market Outlook
Currently, commercial microneedle products are concentrated in the medical aesthetics field (e.g., German Dermaroller), while the pharmaceutical sector stands on the cusp of a breakthrough. International giants like 3M (MTS system) and BD (Soluvia microneedle injector) have launched commercial products primarily for insulin and vaccinations. Domestically, companies like BIOE and Sinderm have achieved breakthroughs in the mass production of dissolving microneedles, establishing automated production lines with an annual output in the tens of millions.
Despite the promising prospects for vaccines, diabetes, oncology, and ophthalmology, challenges remain regarding regulatory standards, manufacturing consistency, and cost control. Nevertheless, with continuous advancements in material science and micro-nano processing, the "tiny needle" is poised to unleash immense industrial value in the fields of precision medicine and global healthcare.
